SEC Filing Details

We are a clinical-stage biopharmaceutical company leveraging our proprietary next-generation, non-viral gene engineering technologies to create life-saving cell and gene therapies for patients with high unmet medical need.

SEC Filing Details

Document Details

Form
Filing Date
May 12, 2022
Document Date
Mar 31, 2022
Form Description
Quarterly report which provides a continuing view of a company's financial position
Filing Group
Quarterly Filings
Company
Poseida Therapeutics, Inc.
Issuer
Poseida Therapeutics, Inc.